FDA grants orphan drug status to Octant’s OCT-980 for RP
The FDA has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa.
The FDA has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa.